The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota by Molly K Gibson et al.
ReviewMolly K. Gibso†M.K.G. and M.W.P.
0022-2836/© 2014 ElseviThe Yin and Yang of Bacterial Resilience in
the Human Gut Microbiotan1, †, Mitchell W. Pesesky1, † and Gautam Dantas1, 2, 3
1 - Center for Genome Sciences & Systems Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
2 - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
3 - Department of Biomedical Engineering, Washington University, St. Louis, MO 63130, USA
Correspondence to Gautam Dantas:WashingtonUniversity School ofMedicine, Center forGenomeSciences andSystems
Biology, 4444 Forest Park Avenue, Room 6215, Campus Box 8510, Saint Louis, MO 63108, USA. dantas@wustl.edu
http://dx.doi.org/10.1016/j.jmb.2014.05.029
Edited by J. L. SonnenburgAbstract
Thehumangut is home to trillionsofmicrobes that formasymbiotic relationshipwith thehumanhost.Duringhealth,
the intestinal microbiota provides many benefits to the host and is generally resistant to colonization by new
species; however, disruption of this complex community can lead to pathogen invasion, inflammation, anddisease.
Restoration and maintenance of a healthy gut microbiota composition requires effective therapies to reduce and
prevent colonization of harmful bacteria (pathogens) while simultaneously promoting growth of beneficial bacteria
(probiotics). Here we review the mechanisms by which the host modulates the gut community composition during
health and disease, and we discuss prospects for antibiotic and probiotic therapy for restoration of a healthy
intestinal community following disruption.
© 2014 Elsevier Ltd. All rights reserved.Introduction
The human intestinal microbiota is continually
subject to a wide variety of perturbations, including
host immune response, nutritional variations, and the
invasion of new species. Even in the face of these
affronts, the gutmicrobiota is generally stable over time
[1] due to the resilience of commensal microbes
to survive under continuous challenge. This stable
microbial community consistently provides a set of
services to its human host, including protecting against
enteric pathogens [2], liberating nutrients from food [3],
and signaling immune system regulation [4]. When the
healthy gut microbiota is disturbed and one of these
services breaks down, there is an urgent need to
restore a healthy configuration. This is a daunting task
for researchers and clinicians as the optimal compo-
sition of healthy, normal-functioning, gut microbiota is
still unclear. Modulation of the gut microbiota through
antibiotic therapy (to eliminate pathogenic bacteria)contributed equally to this work.
er Ltd. All rights reserved.and probiotic and prebiotic administration (to pro-
mote growth of beneficial bacteria) has been shown
to be effective treatment strategies for restoring
healthy function; however, they are not without their
challenges.
Historically, antibiotics have been largely effective at
eliminating enteric pathogens, but the continual rise
in rates of antibiotic resistance [5], through mutation
and horizontal gene transfer (HGT), has necessitated
development of new treatment strategies to fight
pathogenic bacteria. Complicating matters further,
antibiotic treatment often perturbs the highly diverse
gut community and can lead to a decrease in
microbiota-mediated colonization resistance, some-
times resulting in colonization and growth of resistant
pathogens [6]. The same colonization resistance
encoded by the commensal microbiota that helps
protect against pathogen invasion can also be a
significant obstacle in effective probiotic therapy. With
the continuing spread of antibiotic resistance and the
growing prospects for probiotic therapy, new research
has focused on the challenges that bacteria face in
the human intestine—how we can increase thoseJ. Mol. Biol. (2014) 426, 3866–3876
3867Review: Resilience in Gut Microbiotachallenges for pathogens and how we can engineer
probiotics to overcome those challenges in an
attempt to rescue and maintain normal gut microbi-
ota function.
Challenges to bacterial survival and colonization
of the gut environment
Host modulation mechanisms of gut microbial
communities
The mammalian large intestine seems like an ideal
environment for bacterial life, with a regular flow of
nutrients and protection from environmental fluctua-
tions; however, microbial residents also face many
challenges for survival and growth.One of the greatest
challenges that bacteria face in the large intestine is
the very mechanism that brings nutrients to them:
peristalsis. It is estimated that peristalsis removes tens
of millions of viable bacterial cells from the vertebrate
intestinal environment each day [7]. A recent genetic
screen in nematodes identified several defects in
peristalsis that lead to hypersusceptibility to patho-
genic infection [8]. In order to successfully survive in
and colonize the human gut, many bacteria have
evolvedmachinery specialized for adhesion to human
epithelial cell receptors, and these “adhesins” have
been shown to be necessary for persistence of
several strains in the gut microbiota [9–12]. The
human host, in turn, evolved a part of the adaptive
immune system to block association with the epithe-
lium, secretory immunoglobulin A (SIgA). SIgA is
secreted into the intestinal mucosa in large quantities
and, like other antibodies, is produced against specific
surface antigens but has also been shown to interact
with somebacterial adhesins througha separate, non-
specific binding domain [13,14]. For both its specific
and non-specific binding mechanisms, it is believed
that SIgA binds bacteria in themucus layer and blocks
them from adhering to or invading intestinal epithelial
cells. Using SIgA targeted to lipopolysaccharide and
the intestinal pathogen Shigella flexneri, Mathias et
al. demonstrate that SIgA not only blocks proteins
that mediate binding or invasion but also can cause
agglutination of the target bacteria, slowing their
growth rate and preventing contact with intestinal
epithelial cells [15]. The bacteria bound by SIgA are
then removed from the intestine by mucociliary
movements [13].
Thehumanhost alsodeploysmoredeadlymeasures
tomodulatebacterial communities in the large intestine,
including the oxidative stress and antimicrobial peptide
(AMP) components of the innate immunesystem.Each
of these systems has broad antimicrobial activity,
making them a challenge for pathogenic and symbiotic
bacteria alike. Oxidative stress in the intestinal envi-
ronment is caused by a variety of reactive oxygen
species (ROS) and reactive nitrogen species (RNS),
including peroxide, superoxide, and nitric oxide [16,17].These highly reactive molecules damage all forms
of cellular macromolecules and show no specificity for
organism type. Because of the damage it can cause
to human cells, oxidative stress is generally only
employed by the immune system when the body
senses a serious assault. Gut epithelial cells produce
ROSandRNSprimarily during infrequent inflammatory
responses [16–19] and this production is greatly
escalated during inflammatory bowel disease (IBD)
[20]. Bacteria in the human intestinemust be resilient to
oxidative stress if they are to survive and stably
colonize the human gut.
AMPs are a broad class of molecules that include
the α- and β-defensins, RegIIIα, and cathelicidins in
humans [21]. Most known AMPs act on the bacterial
outer membrane or cell wall, which leads to loss of
cell integrity, but some AMPs have been shown to
have additional intracellular targets, including DNA,
RNA, andprotein synthesis [22]. AsAMPs targeting the
cell membrane usually recognize conserved structural
molecules, such as Lipid A, rather than proteinaceous
receptors, they are generally active against broad
classes of bacteria, rather than specific strains [21].
Unlike ROS and RNS, some AMPs in the large
intestine, such as α-defensins, are expressed consti-
tutively, though recent microarray analysis has shown
significantly higher α-defensin expression in inflamed
versus non-inflamed intestinal tissue [23]. Other AMPs
are activated by the presence of specific bacterial
strains. For instance, recent work in gnotobiotic mice
and in human tissue culture has shown that mouse
RegIIIγ and its human homolog RegIIIα are induced in
response to introduction of Bifidobacterium breve, but
not a commensal Escherichia coli strain [24]. Regard-
less of the trigger for AMP expression, their broad
activity ensures that much of the microbiota will be
affected whenever AMPs are deployed.Microbe–microbe competition and niche specificity
In addition to challenges imposed by the human
host, intestinal microbes also face competition from
each other in order to survive. The primary driver
of competition between microbes is niche specificity
and nutrient availability. The niche specificity of the
majority of microbes remains unclear; however,
nutrient requirements have been identified for a few
key gut microbiota residents [25–28]. A study of
oligosaccharide usage found that Bifidobacterium
infantis, a common member of the infant microbiota,
relies upon oligosaccharides from milk, while Bac-
teroides thetaiotaomicron, common in infant and
adult microbiotas, can utilize oligosaccharides from
both milk and the mucus layer of the large intestine
[29]. This highlights the importance of carbon metab-
olism in long-term survival in the microbiota. Further-
more, it has been demonstrated that niches within the
gut environment are saturable and can only support a
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tition for niches that favors established strains over
invading strains. This dynamic was made evident
by Lee et al., who showed that a gnotobiotic mouse
mono-colonized with Bacteroides fragilis will block
colonization by a second inoculation of the same
strain. They also reported that this effect is generaliz-
able to three additional Bacteroides strains [30].
Strains in an established microbiota can employ
several strategies to outcompete invading strains.
One is physical exclusion: B. thetaiotaomicron has
been found to attach to food sources in the intestinal
environment of a gnotobiotic mouse [31], which would
give B. thetaiotaomicron an advantage in accessing
essential nutrients over free floating bacteria. Other
work has shown that members of the microbiota can
deploy their own antimicrobials to gain a competitive
advantage [32]. Some pathogens have evolved
strategies to circumvent direct competition, such as
Salmonella typhimurium, using hydrogen generated
by themicrobiota as an electron source in early stages
of infection [33].
The niches available to the microbiota and invading
strains will differ between individuals and within an
individual over time, depending upon a wide variety of
factors such as diet [34] and host mucus composition.
Recently, McNulty et al. utilized a model community
in gnotobiotic mice to examine fitness changes in
response to dietary changes, focusing onBacteroides
cellulosilyticus WH2. They found WH2 to be very fit
in both high-fat and low-fat diets, while the other
strains in the model community showed more
variable fitness [34]. In addition, host mucus compo-
sition, driven by host genetics, was shown to affect
microbiota composition by Kashyap et al. using
gnotobiotic mice with and without a functional fucosyl-
transferase gene [35].Anthropogenic antibiotics
In addition to challenges imposed by the human
host immune system and cohabitating microbes, the
human gut microbiota is often exposed to high levels
of anthropogenic antibiotics (i.e., antibiotic use in the
clinic and in agriculture). Antibiotic therapy can result in
drastic changes to the gutmicrobiota composition, with
some changes persisting for years following treatment
[36–39]. These changes are often asymmetric, as
some bacteria have higher susceptibility than others
to any particular antibiotic treatment. However, the
popularity of broad-spectrum antibiotics, such as
the β-lactams, means that the majority of human gut
microbes face challenges imposed by common
antibiotic therapy. Even among the survivors, fitness
can be variable—some species increase fitness
without competitors, while others cannot survive with
the loss of other bacterial strains that they depend on
[38,39].Reducing gut colonization and growth of harmful
bacteria
Pathogen resilience mechanisms to host immune
response
In spite of the apparent challenges to growth and
survival in the human intestine, enteric pathogens are
still able to invade and, in somecases, even thrive. The
various components of the human immune system
have evolved to identify and eliminate pathogenic
bacteria while allowing symbiotic species to remain. In
turn, pathogenic bacteria have had the opportunity to
evolve complex systems to defend against attacks by
the human immune system or even to subvert them
for their own gain [19]. For instance, Vibrio cholerae
strains have been shown to avoid SIgA by down-reg-
ulating certain receptors in vivo [40], while pathogenic
E. coli strains can express a specific SIgA binding
antigen that interferes with immune signaling [41].
Resistance toAMPs has also been observed primarily
though avoidance by modifying target molecules
[42,43], while oxidative stress resistance takes the
form of detoxifying enzymes such as catalase,
peroxidase, and superoxide dismutase [44,45]. One
way that researchers have sought to complement the
immune system and overcome pathogen resilience is
through the use of AMPs not naturally produced by the
humanhost [21,22]. These antibiotics would have the
advantages of AMPs, such as low levels of
resistance and structural similarity to natural products
of human cells, but could be administered similar to
other anthropogenic antibiotics. Unfortunately, the first
AMP antibiotics to be used, the polymyxins [46], also
block eukaryotic translation and thus show toxicity to
human cells [47]. Continued work in this field may yet
yield new, safe, antimicrobial compounds, but for now,
clinicians must work with more traditional antibiotic
classes.Antibiotic treatment strategies for combating increasing
pathogenic resistance
The rapid evolution and expansion of antibiotic
resistance in pathogenic bacteria has made treating
infectious disease, while allowing growth of healthy
commensal microbes, particularly challenging. Patho-
genic bacteria haveproven to be exceptionally resilient,
continually evolving resistance to every antibiotic that
has been deployed against them within a short period
after introduction [5]. For a brief period, the rise in
antibiotic resistance was matched by the development
of new antibiotics, but in recent decades, antibiotic
development has not kept pace [48], resulting in the
need for new interventions for treatment of infectious
disease.
Three major strategies have been proposed to keep
our current arsenal of antibiotics relevant: synthetic
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Fig. 1. Antibiotic therapy increases prevalence of antibiotic
resistance available to pathogens harbored in the commensal
microbiota. (a) Human intestinal microbiota is invaded by a
pathogen. (b) With antibiotic treatment, the pathogen is
eliminated along with much of the commensal community.
Several strains survive by acquiring a multidrug resistance
plasmid from another community member. (c) Pathogen
invades recovered community. (d) During subsequent antibi-
otic treatment, the pathogen has an increased likelihood of
acquiring the multidrug resistance plasmid.
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Each of these strategies is applied to eliminate
pathogens, but they oftenhavehigh collateral damage,
disturbing the entire gut microbiota community. Syn-
thetic tailoring is the modification of side groups in
an antibiotic molecule to extend its effectiveness or
circumvent antibiotic resistance, while maintaining the
core antibiotic mechanism [49]. For example, the
β-lactams are a class of antibiotics that have under-
gone several levels of modification since penicillin
was first discovered. The effectiveness of penicillin is
confined to specific Gram-negative bacteria, but
synthetic tailoring generated new antibiotics such as
piperacillin and methicillin that have expanded activi-
ty [50]. The major limitation of synthetic tailoring is
that it does not change the fundamental mechanism
of the antibiotic. While synthetic tailoring can bypass
some types of antibiotic resistance, for others, a
single antibiotic resistance gene can give resistance
to an entire class of antibiotics, and the latter form of
resistance gene is increasing in prevalence. For
instance, the recently discovered, plasmid-born kpc
and ndm genes encode for enzymes that can degrade
all types of β-lactams, and prevalence of these genes
continues to increase in hospitals worldwide [56,57].Antibiotic combinations have been used to treat
organisms for which a single antibiotic treatment is
insufficient, and successful combinations often exhibit
synergy between the constituents. In a synergistic
interaction, the effectiveness of the combination of
drugs at a given concentration is greater than the
effectiveness of either antibiotic on its own at that
concentration. The major advantage of synergistic
combinations is that they lower the total drug
concentrations needed for killing, which can reduce
the toxicity of the treatment to human cells [51,53].
Unfortunately, while lower total concentrations are
an advantage in terms of toxicity, they are a
disadvantage in terms of evolution of resistance,
as bacteria evolve resistance more quickly to
synergistic drug combinations than to the drugs
used singly [52]. This occurs because individual
drugs are dosed at sub-therapeutic concentrations,
resulting in bacteria facing a lower evolutionary
barrier to become resistant to each component of a
combination. Once a bacterium evolves resistance
to one component, the synergy is broken and other
components are no longer at killing concentrations,
overall increasing rates of evolution of resistance.
This downside has been explicitly demonstrated for
two-drug combinations [52], but the theoretical
principle may also apply for higher-order synergistic
compound combinations.
While antibiotic cycling is an established concept
[58–60], the ideahas received renewed recent interest
in the context of the phenomenon of collateral
antibiotic sensitivity. An antibiotic is considered to
confer collateral sensitivity if resistance evolved to
that antibiotic makes a bacterium more susceptible to
another antibiotic, compared to the wild-type popula-
tion [55]. In some cases, two antibiotics can be
reciprocally collateral sensitive, where resistance
evolved to either antibiotic increases susceptibility to
the other. In this case, it has been proposed that one
antibiotic could be applied until resistance to that
antibiotic ismanifested and then treatment switched to
the other [54]. This cycling process could be repeated
until the infection is cleared, and since exposure to
each antibiotic selects for susceptibility to the other,
there would be no net evolution of resistance. This
procedure holds much promise, but cycling based on
reciprocal collateral sensitivity has yet to be imple-
mented clinically, and it is not known how generaliz-
able collateral sensitivities are between species or
even strains.The commensal resistome as a resilience factor
Each of the antibiotic treatment strategies out-
lined above provides benefits for treating pathogens
individually, but they do not adequately address the
additional resilience factors available for transfer to
pathogens with access to the commensal microbiome.
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to the increase in antibiotic resistance, as evidencedby
the worldwide spread of specific β-lactamases [48].
The various mechanisms of HGT have been exten-
sively reviewed elsewhere [61,62], but one of their
cumulative effects has been to greatly expand the
diversity of genetic material available to pathogens,
well beyond what is found in any single genome. The
effects of HGT on clinical outcomes can be seen in
studies of the spread of particular resistance genes,
such as the CTX-M β-lactamases [63]. The complete
set of antibiotic resistance genes present in amicrobial
community is known as the “resistome” and previous
research has shown that the resistome of both human
adult and pediatric intestinal microbiota is far more
diverse thanwhat has been seen in pathogens [64,65].
It has also been shown that the collection of resistance
genes accessible to pathogens extends well beyond
the human microbiota, including animal [66] and soil
[67] environments. Antibiotic therapy, therefore, does
not only select for increased antibiotic resistance in
pathogens but also increased prevalence of antibiotic
resistance genes in microbial communities available
for transfer to pathogens (Fig. 1).
Resistance acquired through HGT poses an im-
mense challenge to clinical treatment of pathogens
because it decouples phylogeny from antibiotic
resistance profile. Tests for taxonomic identity of a
pathogen can return results 1–2 days faster than tests
for antibiotic resistance in rapidly growing pathogens.
For vertically inherited resistance mechanisms, taxo-
nomic identity can provide insight into the susceptibility
and treatment options; however, horizontally trans-
ferred resistance genes can distort this inference. Our
current antibiotic treatment strategies are not adequate
to combat pathogens with access to the commensal
resistome through HGT. Synthetic tailoring and com-
bination therapy provide for selection of increased
antibiotic resistance in the entire microbiota and, thus,
increase the size and diversity of resistomes. Antibiotic
cycling with reciprocally collaterally sensitive antibiotics
shows promise in slowing evolution by mutation, but it
remains to be seenwhether collateral sensitivity cycling
is robust to resistance acquired by HGT. Continued
research into new treatments, especially treatments
that can eliminate pathogens without increasing the
resistome, therefore remains a pressing need.
Promoting growth and colonization by beneficial
bacteria
Colonization resistance for beneficial bacteria
As the fight against multidrug resistance in human
pathogens continues to escalate, there is simulta-
neous interest in promoting the growth and stable
colonization in the human gut by beneficial bacteria
(probiotics) that confer health benefits to the human
host. Probiotics have shown promise in treatmentof a variety of diseases, including IBD [68], atopic
disease [69,70], lactose intolerance [71], pathogen-
associated diarrhea [72], and necrotizing enteroco-
litis [73,74]. A major component of the potential of
probiotic treatment for chronic diseases is the possi-
bility for stable integration of the probiotic into the
microbiota. In this case, colonization of the microbiota
could provide long-term benefits against chronic
conditions such as IBD without the need for continual
administration. However, while probiotics have been
effective at treating gastrointestinal disorders such as
acute infectious diarrhea and necrotizing enterocolitis
in infants and young children [75,76], limited long-term
positive results have been reported from clinical trials
using probiotics in adults, possibly due to the inability
of probiotics to survive and colonize the existing gut
community. For example, E. coli Nissle 1917 and
Lactobacillus rhamnosus GG (LGG) are two clinically
relevant probiotic strains that have been shown to be
effective in treatment of gastrointestinal disease
[75,77,78]. However, after administration is terminated,
both probiotics are cleared from themajority of patients
within weeks. In a study of 48 healthy adult individuals
whowere administeredE. coliNissle for a run-in period
of 17 days, only approximately 45% of the individuals
had detectable levels of the probiotic 2 weeks after
stopping administration [79]. This number continued to
drop continuously until the probiotic was undetectable
in nearly all individuals after 48 weeks. Similarly, in a
randomized trial of 36 individuals who consumed LGG
for a 2-week run-in period, administered as capsule,
yogurt, or cheese, only about 30% of individuals
had detectable levels of LGG after a 3-week period,
regardless of route of administration [80]. In the same
study, other probiotic strains of L. rhamnosus were
undetectable in the gut microbiota of 100% of
individuals after 3 weeks. These results highlight the
importance of understanding and improving resiliency
functions and colonization of probiotic strains in the
human gut microbiota.
Resistance of the stable adult gut microbiota to
colonization by exogenous probiotic species may be
the result of established bacterial strains filling all the
available metabolic and physical niches; thus, newly
introduced organisms must compete against them
for colonization, growth, and expansion. This type of
“colonization resistance”mediated by the composition
of resident gutmicrobiota has long been recognized as
a defense mechanism against pathogenic bacteria
[6,81,82]. Disruption of the commensal microbiota
by antibiotic therapy reduces colonization resistance
through reduction in the commensal microbial abun-
dance and species diversity, thereby freeing niches
and nutrients for exogenous microbes to exploit.
Post-antibiotic enteric pathogen expansion is espe-
cially apparent in Clostridium difficile infections, where
exposure to broad-spectrum antibiotics is the stron-
gest predictor of C. difficile expansion in humans [83]
likely due to niche clearance of commensal microbes.
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and fucose following the relative reduction in commen-
sal microbes by antibiotic therapy enabled the
expansion of two enteric pathogens, C. difficile and
S. typhimurium [84]. C. difficile capitalized upon the
free sialic acid, while S. typhimurium utilized both host
sugars originally liberated by commensal bacteria.Functional mechanisms of gut microbiota colonization
by commensals
Functional mechanisms promoting colonization of
the human gut have been extensively studied in a
handful of important gut microbial inhabitants. Nutrient
availability and utilization has been repeatedly identi-
fied as an important contributor to gut colonization by
various bacterial strains. For example, gene clusters
conserved among intestinal Bacteroides species,
termed polysaccharide utilization loci (PULs), have
been long known to control specificity of polysaccha-
ride use and have been shown to play important roles
in bacterial persistenceand colonization in the gut [85].
As a result, Bacteroides persistence and colonization
in the gut is highly dependent on host diet andmucosal
polysaccharide composition [86]. For instance, the
species-specific bacterial exclusion demonstrated by
Lee et al. (described above) is mediated by a unique
class of PULs. In addition, the authors showed that
these PULs are necessary for Bacteroides coloniza-
tion following disruption of themicrobiota [30]. Nutrient
utilization and specificity also plays important roles in
gut colonization by pathogenic bacteria during inflam-
mation. Deriu et al. demonstrated that administration
of probiotic bacteria E. coli Nissle 1917 reduced
colonization by Salmonella enterica Typhimurium
through competition for limited available iron in the
host gut environment [87].
In addition to nutrient utilization, direct suppression
of the host immune response by commensal bacteria
can allow niche-specific colonization of commensals
on mucosal surfaces while retaining defenses against
bacterial pathogens. A recent study identified a unique
surface polysaccharide of B. fragilis that binds toll-like
receptor 2 on CD4+ T cells, which induces IL-10
production [11]. This, in turn, leads to suppression
of Th17 cell responses and allows colonization of
B. fragilis in the gut epithelium. This has been
proposed as a mechanism by which the human host
discriminates between commensal and pathogenic
bacteria and a mechanism by which beneficial
bacteria evade the challenges imposed by the host
for colonization and survival in the human gut.Promoting growth of beneficial bacteria through
nutrient modulation
Promotion of growth of beneficial bacteria can also
beachieved through the administration of prebiotics ornondigestible carbohydrates that can alter the com-
position of the gut microbiota community by selective-
ly enriching for beneficial bacteria. Oligofructose and
inulin are two of themost studied and well-established
prebiotics, promoting growth of Bifidobacteria and
Lactobacilli, which have specialized in utilization of a
wide variety of carbohydrates [88,89]. In theory,
prebiotics and probiotics can be administered together
in order to promote colonization and growth of the
probiotic. This combination therapy was coined
synbiotics, referring to the synergistic beneficial
effects of both probiotics (beneficial bacteria) and
prebiotics (their associated nutrient needs) over either
component alone. Synbiotics have shown promising
outcomes in treatment of intestinal dysbiosis [90] and
recovery from infection by enteric pathogens [91].Genetic engineering of probiotics for improvedbacterial
resilience and colonization
For the full utility of probiotic therapy to be realized for
chronic conditions, stable colonization of existing gut
microbiota by exogenous microbes is necessary.
Genetic engineering of existing probiotic bacteria to
improve colonization potential holds great promise but
is severely hindered by the lack of an understanding of
universal and transferable mechanisms of bacterial
colonization and fitness in the gut microbiota, such as
tolerance to bile salts [92] or degradation enzymes
present in the intestines (e.g., lysozyme [93]). Biopros-
pecting microbial communities using functional meta-
genomic selections in the host strain of interest
provides a powerful technique for identifying transfer-
able resilience mechanisms and colonization factors
for commensal bacteria and has been previously
utilized as a method for generating a synthetic toolbox
for microbial engineering [94]. Functional screening of
the murine gut microbiota has previously been used to
successfully identify multiple colonization factors that
function in E. coli [95]. The identified genetic determi-
nants are likely of Bacteroides origin; however, the
mechanism by which they enhance intestinal coloni-
zation remains unknown.
Genetic engineering for enhanced probiotic species
still has long ways to go before it can be applied
clinically; however, in vivo bioprospecting of colonizing
human gut microbiota in known probiotics can be
employed in order to speed up the pipeline from
engineering to clinical application (Fig. 2). In addition to
resilience functions for survival in the harsh human gut
environment, the species composition and niche
availability of the resident gutmicrobiota is an important
consideration in enhancing colonization. Given that
universal colonization factors may not exist, functional
selection of colonization factors in gnotobiotic mice
colonized with intact gut microbial communities from
human donors (“humanized” mice) holds promise




























































Fig. 2. Genetic engineering of probiotics for enhanced colonization of gutmicrobiota. Bioprospecting of actively colonizing and
established human gut microbiota, and culture collections including commensal bacteria, can allow identification of transferrable
colonization enhancing factors. Here we show generation of metagenomic libraries in existing probiotics and selection against a
humanized gut microbiota murine model. The identified colonization enhancing factors can then be barcoded, sequenced, and
assembled using methods developed for functional metagenomic selections of antibiotic resistance. Mechanistic follow-up of
identified colonization enhancing factors is essential as an understanding of universal colonization factors is currently lacking.
Engineering of synthetic operons and iterative selections can enable generation of optimized probiotics capable of stable
colonization of the human gut microbiota.
3872 Review: Resilience in Gut Microbiotafor enhanced colonization based on the existing gut
microbiota community composition specific to an
individual. An intermediate step in this ultimate
engineering goal would be identification of colonization
and fitness factors that improve synergy between
existing probiotics and prebiotics. Functional selec-
tions for colonization and fitness factors in the
presence of various prebiotics and in response to
chow representative of human diets worldwide have
the potential to identify transferable metabolic mech-
anisms that utilize specific nutrients that are can be
supplemented and are naturally available in the gut
from the foods we eat. As we learn more about the
niche specificity of gut microbe residents and are able
to predict available niches, we may draw from the
functional toolbox selected in the presence of prebi-
otics in order to engineer probiotics and promote
colonization on a personal basis based on current gut
microbiota composition and/or host diet.
While genetic engineering of probiotics holds great
promise in the era of personalized medicine, this
prospect still faces significant challenges before
translation to a clinical setting. Permanent colonization
of the gut microbiota is desirable for treatment of
chronic diseases; however, as is the focus of thisreview, there are always trade-offs to increased
resiliency and it is necessary to ensure that engineered
probiotics do not bloom and take over the current
microbial community. In addition, as discussed before,
host diet is an important contributor to the fitness of
bacterial inhabitants of the gut based on metabolic
niches, and therefore, functional selection based on
diet and nutritional supplementation may be necessary
to realize the full utility of this approach.Conclusions and Future Perspectives
The gut microbiota is a complex ecosystem, which
during health provides many essential functions to
the host, including carbohydrate metabolism, mod-
ulation of the immune system, and protection against
pathogen invasion. The host is intimately involved in
the maintenance of a healthy gut microbial commu-
nity. Resident bacteria, both harmful and beneficial,
must therefore avoid and adapt to potentially lethal
host immune responses in order to thrive in this
environment. Disruption of this community leads to
heightened immune response in the host and has




3873Review: Resilience in Gut Microbiotaincluding IBD such as Crohn's disease and ulcerative
colitis. In addition, while the immune response has
evolved to identify and eliminate enteric pathogens,
colonization and outgrowth by these organisms often
requires clinical intervention. The administration of
antibiotic therapy for treatment of IBD and pathogenic
infections is often a successful treatment option;
however, it has the potential for high collateral damage,
including enrichment of antibiotic resistance in human
pathogens and the commensal microbiota and reduc-
tion in species composition and diversity. As antibiotic
optionsare continuing to dwindle due to thewidespread
dissemination of antibiotic resistance genes, identifica-
tion of alternative treatment options is necessary.
Probiotic and commensal bacteria show promise at
eliminating and preventing colonization of pathogens
from the gut environment; however, successful stable
introduction of probiotic species into an existing gut
community has met with enormous challenges. Ge-
netic engineering of probiotics to increase colonization
potential is one potential solution, not only in supple-
menting healthy gut microbiota function but also to
outcompete pathogens for the available niches. As
the functional mechanisms of transferrable coloniza-
tion necessary for genetic engineering are still poorly
understood, unbiased bioprospecting of commensal
gut microbiota holds great promise for identification of
these genetic, engineerable, building blocks.
While the exact species and phylogenetic composi-
tion of what constitutes a healthy gut microbiota is still
unclear, there is a continued need to eliminate harmful
bacteria (pathogens) while promoting the growth of
beneficial bacteria (probiotics). A clearer understanding
of resiliencemechanismsof bothharmful andbeneficial
bacterial inhabitants of the human gut microbiota
should enable the design of next-generation treatment
strategies for rescuingandmaintaining thehealth of this
criticalmicrobial ecosystemand, in turn, its humanhost.Acknowledgements
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